Literature DB >> 16701537

In vitro activity of oritavancin (LY333328), vancomycin, clindamycin, and metronidazole against Clostridium perfringens, Propionibacterium acnes, and anaerobic Gram-positive cocci.

Diane M Citron1, Y Y Kwok, Maria D Appleman.   

Abstract

Using an agar dilution method, we determined the in vitro activity of oritavancin, vancomycin, clindamycin and metronidazole against 114 unique clinical isolates of Gram-positive anaerobes. MIC(90)s (microg/mL) for oritavancin were as follows: Clostridium perfringens 1.0, Propionibacterium acnes 0.25, Peptostreptococcus anaerobius 0.25, Peptoniphilus asaccharolyticus 0.5, Finegoldia magna 0.25, Micromonas. micros 0.25, and Anaerococcus prevotii 0.25. On a weight basis, oritavancin is slightly more active than vancomycin against the strains tested. The oritavancin MICs are comparable to those previously reported against staphylococci and enterococci. Oritavancin shows excellent potential for treatment of infections containing Gram-positive anaerobes such as these.

Entities:  

Year:  2004        PMID: 16701537     DOI: 10.1016/j.anaerobe.2004.10.005

Source DB:  PubMed          Journal:  Anaerobe        ISSN: 1075-9964            Impact factor:   3.331


  2 in total

1.  Oritavancin diphosphate.

Authors:  Dennis J Cada; Danial E Baker
Journal:  Hosp Pharm       Date:  2014-12

Review 2.  Profile of oritavancin and its potential in the treatment of acute bacterial skin structure infections.

Authors:  Subhashis Mitra; Usman Saeed; Daniel H Havlichek; Gary E Stein
Journal:  Infect Drug Resist       Date:  2015-07-06       Impact factor: 4.003

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.